Navigation Links
Palatin Technologies to Present at Cowen Annual Health Care Conference on March 19, 2009
Date:3/13/2009

CRANBURY, N.J., March 13 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that it will present at the Cowen and Company 29th Annual Health Care Conference being held at the Boston Marriott Copley Place on Thursday, March 19, 2009 at 11:05 AM.

Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on the Company's corporate and development programs. To access the live audio broadcast or the subsequent archived recording, log onto www.palatin.com.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.

Forward-looking Statements

Statements about future expectations of Palatin Technologies, Inc., including its development programs, proposed indications for its product candidates, pre-clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Palatin's actual results may differ materially from those discussed in the forward-looking statements for various reasons, including, but not limited to Palatin's ability to fund development of its technology, ability to establish and successfully complete clinical trials and pre-clinical studies and the results of those trials and studies, dependence on its partners for certain development activities, need for regulatory approvals and commercial acceptance of its products, ability to protect its intellectual property, and other factors discussed in the Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Palatin Technologies to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008
3. Palatin Technologies Announces Receipt of $4.1 Million from AstraZeneca
4. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
5. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
6. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
7. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
8. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
9. Advanced technologies aim to transform the coaching of top athletes
10. Global Med Technologies(R) Extends Its Worldwide Outreach
11. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... 2017 , ... Guide to FDA and EU Medical Device Regulations: 2017 Edition, ... of the Atlantic devicemakers do business, this fully updated and expanded guide keeps them ... to the full text of the FDA’s regulations in 21 CFR Parts 800 to ...
(Date:6/28/2017)... ... ... David B. Sosin, a founding partner at the law firm Sosin, Arnold ... President for the Illinois State Bar Association , in accordance with the organization’s rules ... 2016 following a state-wide election and served in that capacity for the past year prior ...
(Date:6/28/2017)... Columbia (PRWEB) , ... June 28, 2017 , ... ... (FSE: ZEON) is pleased to announce that a two year study conducted by ... Company's Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a ...
(Date:6/28/2017)... ... June 28, 2017 , ... The Dianne ... the greater Cincinnati metropolitan area, is teaming up with the local chapter of ... children receiving treatment in nearby hospitals. , Ronald McDonald House of Greater Cincinnati, ...
(Date:6/27/2017)... ... 27, 2017 , ... Harbour , a DAO (decentralized autonomous organization) that ... has released their technical specifications . , 2017 has seen an explosion of ... for determining which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ) today ... R. Goodwin , U.S. District Court Judge for the ... entered a case management order in MDL 2325, American ... (the "MDL") that includes a provision requiring plaintiffs in ... specific causation within one hundred twenty (120) days of ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
(Date:5/30/2017)... , May 30, 2017 Therapix Biosciences ... Company specializing in the development of cannabinoid-based drugs, ... a company overview at three upcoming scientific and ... Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: